223 related articles for article (PubMed ID: 22474590)
21. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
23. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
24. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
26. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
27. [Research progress on 18F-FDG PET/CT in evaluating prognosis of patient with diffuse large B cell lymphoma].
Yang Y; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):255-60. PubMed ID: 25687083
[TBL] [Abstract][Full Text] [Related]
28. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
[TBL] [Abstract][Full Text] [Related]
29. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Schiepers C; Filmont JE; Czernin J
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
[TBL] [Abstract][Full Text] [Related]
30. [FDG PET/CT FOR TREATMENT RESPONSE ASSESSMENT IN CANCER].
Bar-Shalom R; Rosengarten O; Heching N; Turner Y; Ruchlemer R
Harefuah; 2021 Jul; 160(7):462-467. PubMed ID: 34263575
[TBL] [Abstract][Full Text] [Related]
31. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
32. Role of functional imaging in the management of lymphoma.
Cheson BD
J Clin Oncol; 2011 May; 29(14):1844-54. PubMed ID: 21482982
[TBL] [Abstract][Full Text] [Related]
33. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
[TBL] [Abstract][Full Text] [Related]
34. [Malignant lymphoma].
Okamoto R
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
[TBL] [Abstract][Full Text] [Related]
35. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
36. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
37. Staging in childhood lymphoma: differences between FDG-PET and CT.
Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
[TBL] [Abstract][Full Text] [Related]
38. [Importance of PET/CT in lymphoma diagnostics].
Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
[TBL] [Abstract][Full Text] [Related]
39. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
40. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
